|
A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: The AGITG GAP study. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Specialised Therapeutics |
|
|
|
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Merck Serono; Novartis; Pfizer; Roche Pharma AG; Specialised Therapeutics |
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Merck Serono; Novartis; Pfizer; Roche Pharma AG; Sanofi; Specialised Therapeutics |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Cochlear; CSL Limited; Sirtex Medical |
Honoraria - GlaxoSmithKline; Sanofi |
Consulting or Advisory Role - Roche Pharma AG; Specialised Therapeutics |
Research Funding - Celgene; Genentech; Roche Pharma AG |
Travel, Accommodations, Expenses - Amgen; Ipsen; Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Specialised Therapeutics |
Travel, Accommodations, Expenses - Ipsen; Merck Serono |
|
|
Research Funding - Specialised Therapeutics |
|
|
Patents, Royalties, Other Intellectual Property - Specialised Therapeutics (Inst) |
|
|
Stock and Other Ownership Interests - Sirtex Medical |
Research Funding - Amgen (Inst); Celgene (Inst); Pfizer (Inst) |